China
华源再生医学 is a China-based startup that specializes in the development and manufacturing of implantable bio-artificial pancreas and artificial kidneys, with a focus on addressing organ repair and regeneration for conditions such as diabetes and end-stage renal disease. The company emphasizes technology research and development while staying committed to a people-centric approach. Their vision is to "build China's best cell therapy and organ tissue engineering company in the Guangdong-Hong Kong-Macao Greater Bay Area." Founded in 2018, their mission is to manufacture implantable bio-artificial pancreas and kidneys and establish a world-class artificial organ base.
The latest milestone for 华源再生医学 was the Seed Round investment on 20 November 2023. The investors in this round included Dyee Capital, Kangyu Capital, West Lake Photonics, Xiamen High-Tech Innovation Center, Kexi Capital, and Topology Capital. This investment underscores the confidence and support from a diverse group of backers, positioning the company for potential growth and innovation in the Health Care industry.
